Hartoun Hartounian - 01 Jan 2025 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: EVP, Chief Operating Officer
Issuer ticker: BCLI
Reported as of: 01 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2025, 17:31:34 UTC
Prior SEC filing: 25 Jun 2024
Next SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Hartoun Hartounian

Key filing fact

Hartoun Hartounian filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 03 Jan 2025.

Key facts

This page summarizes Hartoun Hartounian's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jan 2025, 17:31.

Change

Previous filing in this sequence was filed on 25 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value: $0
Shares: +50,000
Change %: +2500%
Price: $0.000000
Shares after: 52,000
Date: 01 Jan 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Footnote F2

Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024.